Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TATEMENT	OF CHANGES	S IN BENEFI	CIAL OWNE	RSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HEALY JAMES				2. Issuer Name and Ticker or Trading Symbol Y-mAbs Therapeutics, Inc. [YMAB]								5. Relationship of Report (Check all applicable) X Director			, ,	Ssuer Owner				
(Last) (First) (Middle) C/O SOFINNOVA INVESTMENTS, INC.,				3. Date of Earliest Transaction (Month/Day/Year) 01/15/2020								Officer below)	(give title	•	Other below	(specify)				
3000 SAND HILL ROAD, BLDG. 4, SUITE 250					4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) MENLO	PARK C	A	94025											X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(8	State)	(Zip)																	
		Tab	ole I - No	n-Deri	vativ	e Se	curi	ties Ac	quired	, Dis	sposed o	of, or Be	neficia	Ily Owned	l					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution (Year) if any		emed ion Date, /Day/Year	Transaction [Code (Instr. 5		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 and 5)		d (A) or r. 3, 4 and	Beneficial Owned Fo	i Ily	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 and	on(s) nd 4)			(Instr. 4)		
Common Stock 01/1				01/15	5/2020	2020		M		17,778	A	\$11.1	6 17,7	17,778		D				
Common Stock 01			01/15	5/2020	2020			М		8,000	A	\$21.4	5 25,7	,778		D				
Common Stock											2,220	2,220,056		I	See Footnote ⁽¹⁾					
			Table II ·								oosed of converti			y Owned		,		•		
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) if a of (Mo ative		ed ı Date, ay/Year)	4. Transaction Code (Instr. 8)		n of		6. Date Exercisable Expiration Date (Month/Day/Year)		te	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		Derivative Security			10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares							
Non- Employee Stock Option (right to buy)	\$11.16	01/15/2020			М			17,778	(2)		04/24/2028	Common Stock	17,778	\$ \$0	14,2	22	D			
Non- Employee Stock Option (right to	\$21.45	01/15/2020			M			8,000	(3)		06/12/2029	Common Stock	8,000	\$0	8,00	00	D			

Explanation of Responses:

- 1. The Reporting Person is one of the managing members of the general partner of Sofinnova Venture Partners X, L.P. that directly holds the reported securities, and as such, may be deemed to share voting and investment power with respect to such securities. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Ventures Partners X, L.P.
- 2. The option (a) was granted purusant to the Company's 2018 Equity Incentive Plan; (b) represents the right to purchase a total of 32,000 shares; and (c) became exercisable in equal installments beginning on April 24, 2018, which was the date on which the option was granted. Any shares of Common Stock received upon the exercise of such option are subject to a lock-up agreement, which expires on January 27,
- 3. The option a) was granted purusant to the Company's 2018 Equity Incentive Plan; (b) represents the right to purchase a total of 16,000 shares; and (c) became exercisable in equal installments beginning on June 12, 2019 which was the date on which the option was granted. Any shares of Common Stock received upon the exercise of such option are subject to a lock-up agreement, which expires on January 27, 2020.

/s/ James Healy

01/17/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.